Replies to post #880 on Vascular Biogenics Ltd (VBLT)

[Oren1976]

I take a break from forums. The trial in rgbm will meet the primary endpoint not 99% it's by 100% zero doubt. I just believe the results could have been better without avastin. 2 reasons - 1. The complete responder that lived 2 years and 7 months was on vb111 only. 2- the reason there was a progression after first or second dose of vb111 is because the arm of vb111 which is not immune arm starts to work only after 4 or 5 treatments and this progression is not a sign that somebody may learn avastin combo is required.